Responsive Neurostimulation (RNS) in Treatment of Epilepsy in Tuberous Sclerosis
Abstract number :
3.207
Submission category :
4. Clinical Epilepsy / 4C. Clinical Treatments
Year :
2021
Submission ID :
1826724
Source :
www.aesnet.org
Presentation date :
12/6/2021 12:00:00 PM
Published date :
Nov 22, 2021, 06:56 AM
Authors :
Irfan Ali, MD - Baylor College of Medicine; rohini Coorg - Baylor College of Medicine; Daniel Curry - Baylor College of Medicine; Maureen Handoko - Baylor College of medicine; kim Patel - Baylor College of Medicine; Jim Riviello - Baylor College of Medicine; howard weiner - Baylor College of Medicine; cemal Karakas - University of Louiville
Rationale: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic neurocutaneous syndrome with highly variable clinical manifestations involving almost every organ in the body. The majority of the patients experience a seizure in infancy. Responsive Neurostimulation (RNS) is a new tool available to treat drug-resistant epilepsy in patients who are not surgical candidates due to seizure onset from eloquent cortex or multiple brain regions, which is frequently the case in TSC patients.
However, limited literature is available describing the safety and efficacy of RNS in pediatric patients with drug-resistant epilepsy. We aim to review the clinical outcomes of a series of pediatric tuberous sclerosis complex (TSC) patients with drug-resistant epilepsy treated with the RNS system.
Methods: A retrospective chart review of patients treated with RNS device implantation between July 2016 and March 2021 identified six patients who had TSC, and four had at least four months of follow-up at our center.
Results: One patient had more than 50% seizure reduction, and two patients had > 90% seizure reduction, and another patient had 25% seizure reduction at the last clinical follow-up. The average follow-up was 11 months, and no patient experienced device-related complications. The maximum current density was 1-3 micro Coulumbs per centimeter square. All patients reported improvement in Quality of life at clinical follow-ups.
Conclusions: The patients with TSC had a 75% responder rate, with 50% having > 90% seizure reduction after RNS treatment. RNS is safe and effective in treating epilepsy in TSC patients children in our experience.
Funding: Please list any funding that was received in support of this abstract.: No funding was provided for this paper.
Clinical Epilepsy